Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia

Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy (IC). Some patients who are IC candidates instead receive ven/aza. We retrospectively analyzed patients with newly diagnose...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherry, Evan M., Abbott, Diana, Amaya, Maria, McMahon, Christine, Schwartz, Marc, Rosser, Julie, Sato, Audrey, Schowinsky, Jeffrey, Inguva, Anagha, Minhajuddin, Mohd, Pei, Shanshan, Stevens, Brett, Winters, Amanda, Jordan, Craig T., Smith, Clayton, Gutman, Jonathan A., Pollyea, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714726/
https://www.ncbi.nlm.nih.gov/pubmed/34610123
http://dx.doi.org/10.1182/bloodadvances.2021005538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714726/
https://www.ncbi.nlm.nih.gov/pubmed/34610123
http://dx.doi.org/10.1182/bloodadvances.2021005538

Ejemplares similares